Analysts fell to the sidelines weighing in on CureVac (CVAC – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
CureVac (CVAC)
In a report released today, Mani Foroohar from Leerink Partners downgraded CureVac to Hold, with a price target of $4.00. The company’s shares closed last Wednesday at $2.51, close to its 52-week low of $2.34.
According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CureVac with a $11.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
BioMarin Pharmaceutical (BMRN)
In a report released today, David Lebovitz from Citi assigned a Hold rating to BioMarin Pharmaceutical, with a price target of $91.00. The company’s shares closed last Wednesday at $91.20.
According to TipRanks.com, Lebovitz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $111.67 average price target, which is a 20.5% upside from current levels. In a report released yesterday, RBC Capital also maintained a Hold rating on the stock with a $100.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CVAC:
